Rakesh Dixit
President & Chief Executive Officer Bionavigen Oncology
Seminars
Despite ADC’s raging success in oncology in the clinic, translational barriers still plague ADC development, with preclinical activity not matching early clinical safety and efficacy readouts and therapeutic index
As the field turns its attention to advance novel conjugate translation, join your peers to best leverage preclinical tools and understand rationale to effectively characterise safety and efficacy to minimise the ADC translational mismatch
Workshop highlights include:
- Gleaning insights from PDX models alongside emerging capabilities and challenges from in vitro and organoid models
- Understanding translational considerations for novel conjugates including bispecific ADCs and combination therapies
- Delving into in vitro pharmacology studies with high content imaging to better understand ADC trafficking, favourable design characteristics and considerations for nonspecific uptake
- Contextualising the field’s prioritisation of novel ADC payloads and design in next-generation ADC development
- Understanding toxicity challenges and opportunities for novel and dual payload ADCs
- Exploring ongoing development, promise and opportunities of bispecific ADC programmes
Even with 2025 seeing ADCs rival oncology standard of care performance and multiple new regulatory approvals, clinical toxicity still remains the largest hurdle to widen ADC therapeutic index and accomplish widespread impact for patients
Don’t miss this important seminar spanning the breadth of ADC toxicity including in vivo and in vitro model to predict clinical tolerability, harnessing masked payload technology to improve off-target toxicity and clinical mitigation strategies to deliver safer, more effective ADCs
